| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_27a71ddaaa2f5a8c228fc6cb3f3b3098 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-90
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-94
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-71
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-72 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39591
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-241
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-24 |
| filingDate |
2012-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f5cfe1d9d26b8e61a16552934f25fc50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_30b549ac3606fb49694ad82d5c2c0930
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_104323988d6242b525fa48420ff29c82
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_751e8fbf541631cce6ae8b3a29cc3c8f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ad7ecc8a039d58e6d6dbce41b5fc1762 |
| publicationDate |
2014-02-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
MX-2014000739-A |
| titleOfInvention |
TNF-ALFA ANTIGEN UNION PROTEINS WITH INCREDIBLE FCRN UNION. |
| abstract |
The present invention provides antigen binding proteins that specifically bind TNF-alpha. For example novel variants of anti-TNF antibodies, such as adalimumab which show increased binding to the FcRn receptor or increased half-life compared to adalimumab. Compositions comprising antigen-binding proteins and the uses of such compositions in the treatment of disorders and disease are also provided. |
| priorityDate |
2011-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |